BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder

Wang, Yuan; Zhang, Haiyin; Liu, Ying; Wang, Zhen; Fan, Qing; Yu, Shunying; Lin, Zhiguang; Xiao, Zeping

doi:10.1016/j.jad.2015.07.023

Cited by 48 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Asian patients, studies assessing the association between BDNF plasma levels and the BDNF Val66Met polymorphism were negative both in MDD [5,6] and in patients with other disorders [21,22,23,24,25]. Regarding Caucasians, a study in schizophrenia shows results coherent with ours [26] although 2 studies in community samples [16,27] and 1 in patients with eating disorders [28] were negative.…”

Section: Discussionsupporting

confidence: 56%

Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients

et al. 2017

View full text Add to dashboard Cite

Aims: Despite the involvement of the brain-derived neurotrophic factor (BDNF) in the physiopathology of major depressive disorder (MDD), the coherence between the components of the BDNF pathway and their link with the clinical features of MDD are insufficiently studied. We aimed to assess in Caucasian depressed patients the impact of the BDNF Val66Met polymorphism on plasma BDNF levels taking into account the clinical characteristics of MDD. Methods: A total of 328 Caucasian adult MDD patients with a current major depressive episode (MDE) were assessed for the BDNF Val66Met polymorphism, plasma BDNF levels and clinical characteristics of the MDD. Results: Plasma BDNF levels were linearly associated with the BDNF Val66Met genotypes (ValVal: 1,525.9 ± 1,183.3 pg/mL vs. ValMet: 1,248.7 ± 1,081.8 vs. MetMet: 1,004.9 ± 952.8; p = 0.04), Met carriers having lower BDNF levels than ValVal ones. Significant interactions between the Val66Met polymorphism and 3 clinical characteristics - age at onset (p = 0.03), MDD duration (p = 0.04), and number of previous MDE (p = 0.04) - were evidenced for plasma BDNF levels. Indeed, in Met carriers, but not in ValVal ones, plasma BDNF levels were negatively correlated with age at onset and positively correlated with MDD duration and number of previous MDE. Conclusion: Our results show a measurable, coherent, and functional BDNF pathway based on the BDNF Val66Met polymorphism and plasma BDNF levels in patients with a current MDE. This pathway is related to the clinical course of major depression, plasma BDNF levels being associated with the long-term history of MDD in Met carriers. Further studies assessing central BDNF are needed to understand the underlying mechanisms of this association.

show abstract

Section: Discussionsupporting

confidence: 56%

Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Table 2 shows reported genotypic and allelic frequencies; four studies reported associations with GAD. 22,23,25,26 Seven polymorphisms (BCL2, DRD2, HTR1A, BDNF, MAOA, 5HTT, TPH) had their genotypic and allelic frequencies reported. Among these, the following association with Generalized Anxiety Disorder were described: (a) the Met allele of the BDNF gene was associated with increased BDNF protein levels in GAD; 22 (b) the 941T allele of the MAOA gene was associated with GAD in females; 23 (c) the SS genotype and S allele of the 5-HTT gene were associated with GAD; 26 (d) the A allele of the ERS2 gene was associated with an increased risk of GAD, but the authors failed to report the frequency of allele occurrence.…”

Section: ■ Resultsmentioning

confidence: 99%

“…4 In another study, the Val66Met polymorphism was not associated with GAD and showed no Genetic Polymorphisms and Generalized Anxiety Disorder Alves V M influence on BDNF plasma levels. 25 Few studies have been conducted about serum BDNF as a biomarker in patients with anxiety disorders. 20 Finally, it should be noted that the Met allele of the BDNF Val66Met polymorphism has been implicated in anxiety in animal models.…”

Section: ■ Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Generalized Anxiety Disorder: a systematic review

Alves¹,

Moura²,

Correia³

et al. 2017

Medical Express

View full text Add to dashboard Cite

“…65 However, Val66Met variation was associated with neither GAD nor BDNF plasma levels in a Chinese Han population with GAD. 66 In addition, polymorphisms both in regulator of G-protein signaling 2 (RGS2) and neuropeptide Y (NPY) genes have been shown to modify risk of post-disaster GAD under conditions of high stressor exposure among adults living in areas affected by the 2004 Florida Hurricanes 67,68 and few single-nucleotide polymorphisms (SNPs) in proteasome modulator 9 (PSMD9) gene were in linkage with GAD in Italian families with type 2 diabetes. 69 …”

Section: Genetic Biomarkersmentioning

confidence: 99%